NAD(P)H: quinone oxidoreductase 1 activatable toll-like receptor 7/8 agonist designed for precise immunotherapy

An NQO1-responsive precursor, named R848-QPA, has been developed to evoke an anti-tumor immune response. R848-QPA can induce innate immune activation when activated by overexpressed NQO1 in the tumor microenvironment while showing lower activity in NQO1-deprived environments. This strategy provides a new method for the development of tumor-microenvironment-responsive prodrugs for antitumor immunotherapy.

Automated summary

An NQO1-responsive precursor called R848-QPA has been developed to induce an anti-tumor immune response. When activated by overexpressed NQO1 in the tumor microenvironment, R848-QPA can activate innate immunity, but it shows lower activity in NQO1-deprived environments. This strategy offers a new approach for the development of tumor-microenvironment-responsive prodrugs for antitumor immunotherapy.